» Articles » PMID: 29555570

Reproducibility of MRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization

Overview
Journal Acad Radiol
Specialty Radiology
Date 2018 Mar 21
PMID 29555570
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale And Objectives: To evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) using multiphasic computed tomography.

Materials And Methods: The institutional review board approved this retrospective study. We evaluated 97 patients who underwent TACE (60 conventional TACE [cTACE] and 37 drug-eluting bead TACE [DEB-TACE]) for HCC from 2010 to 2014. Four radiologists evaluated pairs of dynamic liver CTs scanned within 2 months before and after TACE based on mRECIST. Assessment of intra- or interobserver reproducibility for response categorization and sum of long diameter were evaluated using weighted kappa statistics (κ) and intraclass correlation coefficients, respectively. The relationship between concordance of target lesion selection and agreement of target lesion response was evaluated using Fisher exact test.

Results: Intraobserver reproducibility for overall response was moderate to excellent (κ = 0.525-0.865). Interobserver reproducibility was improved on the second review compared to the first review and it was good in both treatment groups (κ = 0.627 for cTACE and 0.602 for DEB-TACE). Between the two treatment methods, intra- or interobserver reproducibility was better after cTACE than DEB-TACE. Intraclass correlation coefficients for sum of long diameter measurement showed excellent intra- or interobserver reproducibility. The concordance rate of target lesion selection was significantly higher for patients with radiologists' agreement for target lesion response than patients with disagreed response (P = .003).

Conclusions: The intra- and interobserver reproducibility of mRECIST in patients with HCC after TACE was moderate to excellent, and the reproducibility was slightly better after cTACE than DEB-TACE.

Citing Articles

Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.

Hsu W, Lai H, Chen C, Wang H, Chuang P, Tsai M Am J Cancer Res. 2023; 13(2):654-668.

PMID: 36895987 PMC: 9989621.


Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.

Zhou W, Lv Y, Hu X, Luo Y, Li J, Zhu H Front Oncol. 2022; 12:957737.

PMID: 36387217 PMC: 9650244. DOI: 10.3389/fonc.2022.957737.


The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy.

Muller L, Gairing S, Kloeckner R, Foerster F, Schleicher E, Weinmann A Cancer Imaging. 2022; 22(1):54.

PMID: 36153569 PMC: 9509639. DOI: 10.1186/s40644-022-00487-x.


Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.

Hsu W, Wang H, Chen C, Lai H, Chuang P, Tsai M Am J Cancer Res. 2022; 11(12):6173-6187.

PMID: 35018250 PMC: 8727811.


Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Huicochea Castellanos S, Pagano A, Plodkowski A, Girshman J, Hellmann M, Rizvi H Lung Cancer. 2021; 161:60-67.

PMID: 34536733 PMC: 8683158. DOI: 10.1016/j.lungcan.2021.08.020.